Company Overview of Zenith Epigenetics Corp.
Key Executives for Zenith Epigenetics Corp.
Senior Vice President of Operations
Compensation as of Fiscal Year 2014.
Zenith Epigenetics Corp. Key Developments
Zenith Epigenetics Corp. Announces Suspension of its Clinical Development Efforts with ZEN-3365
Oct 24 14
Zenith Epigenetics Corp. announced that due to recent business developments it is suspending its clinical development efforts with ZEN-3365, one of its proprietary BET inhibitors. This decision is unrelated to the preclinical safety and efficacy attributes of ZEN-3365. The company will continue to aggressively advance preclinical development activities with another differentiated proprietary small molecule BET inhibitor and is targeting the second half of 2015 to initiate Phase 1 clinical trials in oncology.
Zenith Epigenetics Corp Announces Management Changes
Sep 8 14
Zenith Epigenetics Corp. announced that it has appointed Joy Zhu as Chief Medical Officer, Sanjay Lakhotia as Chief Business Officer, and Michael Yakes as Vice President Drug Discovery and Exploratory Development. Prior to joining Zenith, Dr. Zhu held leadership positions at SUGEN/Pfizer, SBIO Pte Ltd, Amgen, JNJ, and Novartis. Most recently, Dr. Zhu led oncology clinical development at Halozyme Therapeutics.
Zenith Epigenetics Corp., Annual General Meeting, Oct 08, 2014
Jul 28 14
Zenith Epigenetics Corp., Annual General Meeting, Oct 08, 2014., at 10:30 Mountain Daylight. Location: TELUS Convention Centre, , The Glen Room 206. Agenda: To receive the audited financial statements of the company for the year ended April 30, 2014 and the report of the auditors thereon; to set the number of directors to be elected at the Meeting at six; to elect directors for the ensuing year; to appoint auditors for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; and to transact such other business that may properly come before the meeting or adjournments thereof.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 23, 2014
March 14, 2014
Most Searched Private Companies
Sponsored Financial Commentaries